VERTANICAL is a globally leading biopharmaceutical company focused on the development of innovative therapies to treat of chronic pain. Our work is driven by a clear vision: A World free of Chronic Pain. After over eight years of rigorous research and development, we have developed VER-01, a groundbreaking cannabinoid-based therapy for chronic pain. Our goal was to develop a pain medication that goes beyond purely analgesic (pain-relieving) effects but also provides significant benefits in treating common comorbid symptoms of chronic pain, such as sleep disorders and impaired physical function. Building on our success in the clinical development, we are pursuing the ambitious mission to set new standards in pain therapy and establish VER-01 as the leading therapy for chronic pain by 2030.
Company Details
- Employees
- 78
- Address
- Am Haag 14, Gräfelfing,germany
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- vertanical.de
- Keywords
- Adragos Pharma.
- HQ
- Gräfelfing
Vertanical Questions
Vertanical's website is vertanical.de
Vertanical's LinkedIn profile is https://de.linkedin.com/company/vertanical-gmbh
Vertanical has
78 employees.
View email and phone details for 78
employees at Vertanical.
Vertanical's industry is
Pharmaceutical Manufacturing
Vertanical's top competitors are
Msd Deutschland,
Kijimea (Synformulas Gmbh),
Adragos Pharma,
Aenova Group,
Foodora,
Denk Pharma,
Pharmasgp Holding Se,
Futrue,
Daiichi Sankyo Europe Gmbh,
Inverna Therapeutics.
Vertanical's categories are Pharmaceutical Manufacturing
